A Phase 3 interventional study of Rosuvastatin and Atorvastatin in Coronary Atherosclerosis, sponsored by AstraZeneca. Completed at 195 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-07-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.
Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one has the largest enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 2nd registered.
4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 30–60
Prof. Maurovich-Horvat Pál · Sites in Hungary
Ages 45–75
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,333 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 175 across the 34 interventional studies. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 34 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
25 studies in Coronary Artery Disease by AstraZeneca: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 11 (46%) have results posted.
Among the 25 studies in Coronary Artery Disease by AstraZeneca, this one is the 4th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2008, is one of 7 in phase 3, and was the 5th registered.
AstraZeneca’s Coronary Artery Disease studies by the year they started, since 2001.
3 of the studies testing rosuvastatin in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03169985Samsung Medical CenterRandomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque | 2027-01-28 |
| NCT05850091Massachusetts General HospitalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine | 2027-06-01 |
| NCT06767345Korea University Anam HospitalComparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies testing rosuvastatin in Coronary Artery Disease, from their registry updates:
Among AstraZeneca’s 25 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rosuvastatin 20 mg distributed in 2-week run-in period
Drug: Rosuvastatin
Atorvastatin 40 mg distributed in 2-week run-in period
Drug: Atorvastatin
Rosuvastatin 40 mg distributed in core 2-year study
Drug: Rosuvastatin
Atorvastatin 80 mg distributed in core 2-year study
Drug: Atorvastatin
capsule, oral, once daily
Also known as: Crestor
capsule, oral, one daily
Also known as: Lipitor
Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)
Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as: \[sum(EEMcsa-LUMENcsa)/sum EEMcsa\]\*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.
Time frame: End of study (Week 104)
Numbers of Patients Showing Regression in PAV
Regression defined as a change from baseline in PAV \< 0
Time frame: End of study (Week 104)
Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)
Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.
Time frame: End of study (Week 104)
Numbers of Patients Showing Regression in TAV
Regression defined as a change from baseline in TAV \< 0
Time frame: End of study (Week 104)
Total Cholesterol Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
LDL-C Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
HDL-C Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
Triglycerides Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
Non-HDL-C Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
LDL-C/HDL-C Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
Total Cholesterol/HDL-C Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
Non-HDL-C/HDL-C Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
Apolipoprotein B Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
Apolipoprotein A-1 Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
Apoliprotein B/Apolipoprotein A-1 Blood Level
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
VLDL-C During the 104 Week Treatment Period
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
Time frame: 104 weeks
2333 Coronary Artery Disease (CAD) patients with clinical indication for coronary angiography were randomized to Part A, the 2-week run-in period. Of these, 1578 patients were treated and 1385 completed Part A. The 1385 patients completing Part A were then randomized to Part B the core study period of 104 weeks of treatment.
| Milestone | Rosuvastatin 20 mg | Atorvastatin 40 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|---|
| Started | 1167 | 1166 | 0 | 0 |
| Received treatment | 783 | 795 | 0 | 0 |
| Completed | 695 | 690 | 0 | 0 |
| Not completed | 472 | 476 | 0 | 0 |
| Withdrew: Adverse event | 12 | 15 | 0 | 0 |
| Withdrew: Protocol violation | 406 | 409 | 0 | 0 |
| Withdrew: Withdrawal by subject | 43 | 40 | 0 | 0 |
| Withdrew: Lost to follow-up | 7 | 6 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Safety reasons | 0 | 1 | 0 | 0 |
| Withdrew: Ivus not available | 4 | 4 | 0 | 0 |
| Milestone | Rosuvastatin 20 mg | Atorvastatin 40 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 694 | 691 |
| Received treatment | 0 | 0 | 691 | 689 |
| Intent-to-treat population | 0 | 0 | 520 | 519 |
| Completed | 0 | 0 | 546 | 547 |
| Not completed | 0 | 0 | 148 | 144 |
| Withdrew: Adverse event | 0 | 0 | 46 | 49 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 55 | 54 |
| Withdrew: Lost to follow-up | 0 | 0 | 20 | 9 |
| Withdrew: Protocol violation | 0 | 0 | 13 | 16 |
| Withdrew: Safety reasons | 0 | 0 | 2 | 3 |
| Withdrew: Study specific discontinuation criteris | 0 | 0 | 6 | 6 |
| Withdrew: Ivus not available | 0 | 0 | 3 | 2 |
Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as: \[sum(EEMcsa-LUMENcsa)/sum EEMcsa\]\*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.
| Percent change | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV) | -1.22 (-1.52 to -0.90) | -0.99 (-1.19 to -0.63) |
Regression defined as a change from baseline in PAV \< 0
| Participants | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Numbers of Patients Showing Regression in PAV | 356 | 328 |
Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.
| mm^3 | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV) | -6.39 (-7.52 to -5.12) | -4.42 (-5.98 to -3.26) |
Regression defined as a change from baseline in TAV \< 0
| Participants | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Numbers of Patients Showing Regression in TAV | 371 | 336 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| mg/dL | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Total Cholesterol Blood Level | 139.38 ± 1.24 | 144.05 ± 1.23 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| mg/dL | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| LDL-C Blood Level | 62.64 ± 1.00 | 70.18 ± 0.99 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| mg/dL | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| HDL-C Blood Level | 50.43 ± 0.54 | 48.64 ± 0.53 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| mg/dL | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Triglycerides Blood Level | 132.50 ± 2.44 | 126.58 ± 2.43 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| mg/dL | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Non-HDL-C Blood Level | 88.95 ± 1.15 | 95.41 ± 1.14 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| Ratio | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| LDL-C/HDL-C Blood Level | 1.30 ± 0.02 | 1.50 ± 0.02 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| Ratio | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Total Cholesterol/HDL-C Blood Level | 2.88 ± 0.03 | 3.08 ± 0.03 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| Ratio | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Non-HDL-C/HDL-C Blood Level | 1.88 ± 0.03 | 2.08 ± 0.03 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| mg/dL | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Apolipoprotein B Blood Level | 72.55 ± 0.85 | 75.12 ± 0.85 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| mg/dL | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Apolipoprotein A-1 Blood Level | 146.81 ± 1.03 | 137.68 ± 1.02 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| Ratio | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| Apoliprotein B/Apolipoprotein A-1 Blood Level | 0.51 ± 0.01 | 0.56 ± 0.01 |
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
| mg/dL | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|
| VLDL-C During the 104 Week Treatment Period | 26.05 ± 0.45 | 25.03 ± 0.44 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 20 mg | — | 21/783 (2.7%) | 0/783 (0%) |
| Atorvastatin 40 mg | — | 25/795 (3.1%) | 0/795 (0%) |
| Rosuvastatin 40 mg | — | 194/691 (28.1%) | 210/691 (30.4%) |
| Atorvastatin 80 mg | — | 168/689 (24.4%) | 213/689 (30.9%) |
| Event | Rosuvastatin 20 mg | Atorvastatin 40 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|---|
| Angina PectorisCardiac disorders | 5/783 | 5/795 | 25/691 | 28/689 |
| Angina UnstableCardiac disorders | 0/783 | 2/795 | 17/691 | 11/689 |
| Non-Cardiac Chest PainGeneral disorders | 1/783 | 3/795 | 14/691 | 7/689 |
| Coronary Artery StenosisCardiac disorders | 1/783 | 0/795 | 12/691 | 9/689 |
| Coronary Artery DiseaseCardiac disorders | 0/783 | 0/795 | 10/691 | 4/689 |
| Chest PainGeneral disorders | 0/783 | 0/795 | 7/691 | 7/689 |
| Acute Myocardial InfarctionCardiac disorders | 0/783 | 1/795 | 5/691 | 6/689 |
| Atrial FibrillationCardiac disorders | 0/783 | 1/795 | 3/691 | 6/689 |
| SyncopeNervous system disorders | 0/783 | 0/795 | 3/691 | 6/689 |
| In-Stent Coronary Artery RestenosisInjury, poisoning and procedural complications | 0/783 | 0/795 | 6/691 | 3/689 |
| Event | Rosuvastatin 20 mg | Atorvastatin 40 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|---|
| MYALGIAMusculoskeletal and connective tissue disorders | 0/783 | 0/795 | 99/691 | 91/689 |
| ANGINA PECTORISCardiac disorders | 0/783 | 0/795 | 61/691 | 65/689 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/783 | 0/795 | 50/691 | 43/689 |
| HYPERTENSIONVascular disorders | 0/783 | 0/795 | 36/691 | 40/689 |
| FATIGUEGeneral disorders | 0/783 | 0/795 | 32/691 | 39/689 |
| Age, Categorical(Participants) | Rosuvastatin 40 mg | Atorvastatin 80 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 402 | 395 | 797 |
| >=65 years | 118 | 124 | 242 |
| Age Continuous(years) | Rosuvastatin 40 mg | Atorvastatin 80 mg | Total |
|---|---|---|---|
| Age (yrs) at Week 0 | 57.4 ± 8.60 | 57.9 ± 8.50 | 57.6 ± 8.55 |
| Sex: Female, Male(Participants) | Rosuvastatin 40 mg | Atorvastatin 80 mg | Total |
|---|---|---|---|
| Female | 141 | 133 | 274 |
| Male | 379 | 386 | 765 |
Showing the first 100 of 195 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2008, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin